Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares at $19, above the range of $16 to $18. The company offered 2.0 million more shares than anticipated. At pricing, the company raised 33% more in proceeds than expected.
Dyne Therapeutics plans to list on the Nasdaq under the symbol DYN. J.P. Morgan, Jefferies, Piper Sandler and Stifel acted as lead managers on the deal.
